Preconceived notions about biosimilars-a French experience
Related Experiment Video
Updated: Dec 17, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Jean-David Cohen1, Sonia Tropé2, Pascal Paubel3,4,5
1Rheumatology Department, Lapeyronie Hospital, Montpellier University Hospital Center, Montpellier, France. jd-cohen@chu-montpellier.fr.
Abstract:
Since the arrival of the first biosimilar monoclonal antibodies into the market, many information has been circulating, leading to preconceived notions for patients and healthcare professionals. In a pressing economic context and faced with a growing number of available biosimilars, we (clinician, patient association, biologist, pharmacists, health economists) propose to take stock by trying to distinguish facts from misconceptions.
More Related Videos
07:52A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain
Published on: April 9, 2019
13:14Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Bioequivalence: Overview
Equivalence: In Vitro and In Vivo Bioequivalence
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Bioequivalence of Drugs: Drugs with Multiple Indications